Are You Considering How Best To Manage And Remove Aggregates From Your mAb Process?
Source: MilliporeSigma
Aggregates in mAb therapeutics pose a risk to patients. Are you considering how best to manage and remove aggregates across your template?
Herb Lutz, Global Consultant, opens this 6-part video series with a discussion around the formation of protein aggregates and their regulatory importance. An overview of methods and technologies will also be reviewed for managing or removing aggregates from your mAb process including upstream, chromatography, virus filtration, ultrafiltration/diafiltration (UF/DF), and final formulation.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
MilliporeSigma
This website uses cookies to ensure you get the best experience on our website. Learn more